Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma reported Q3 FY26 operating revenue of INR 754.4 crores, up 10.6% year-on-year and an all-time high, driven by US/North America (up 16.9% to INR 412.4 crores) and Australia/NZ (up 30.1%). EBITDA grew 23.2% YoY to INR 160.7 crores with margin expanding 217 bps to 21.3%, aided by softer raw material prices, better product mix and operating leverage from the Teva facility. Profit after tax rose 8.2% to INR 113.7 crores (EPS INR 2.5). For 9M FY26, revenue grew 9.4% to INR 2,094.8 crores, US business up 24.2% at INR 1,127.3 crores, while UK remained flat due to price erosion. Cash balance stood at INR 824.2 crores, and the company remains debt-free. Management guided to INR 4,000 crore revenue milestone in 2-3 years (FY28-29) and is actively pursuing M&A in Europe.
Strong quarterly performance with margin expansion and a robust cash position supports investor confidence. The US order book of $220M+ and explicit multi-year revenue targets provide visible growth runway, though UK pricing pressure and elevated employee costs remain near-term watchpoints.